Metastatic prostate adenocarcinoma of the dura mater.

Br J Neurosurg

University of Pittsburgh School of Medicine, UPMC Presbyterian Hospital, Department of Neurosurgery, 200 Lothrop Street, Suite B-400, Pittsburgh, Pennsylvania 15213-2582, USA.

Published: October 2000

A 70-year-old man with known metastatic prostate carcinoma to the long bones of the lower extremities, presented with a several day history of lethargy and confusion. CT was interpreted as showing bilateral acute and chronic subdural hematomas (SDH). Upon opening the dura, a yellowish, firm tumor was layered over the frontal convexity. No hematoma was found. Histological examination revealed prostate carcinoma.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688690050175328DOI Listing

Publication Analysis

Top Keywords

metastatic prostate
8
prostate carcinoma
8
prostate adenocarcinoma
4
adenocarcinoma dura
4
dura mater
4
mater 70-year-old
4
70-year-old man
4
man metastatic
4
carcinoma long
4
long bones
4

Similar Publications

Background: It has been more than a decade since fusion prostate biopsy (FPB) has been used in the diagnosis of prostate cancer (PCa). Therefore, patients with a previous history of negative FPB and ongoing suspicion of PCa are beginning to emerge. This study investigated whether the first biopsy type (standard or fusion) should be effective in deciding on a second biopsy.

View Article and Find Full Text PDF

In the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benefits of ICT, its use is complicated by the potential risk of immune-related adverse events (irAEs). One rare but potentially life-threatening irAE is hemophagocytic lymphohistiocytosis (HLH).

View Article and Find Full Text PDF

Bone metastasis and skeletal-related complications are primary causes of mortality in advanced-stage prostate cancer (PCa). Epigenetic regulation, particularly histone modification, plays a key role in this process; however, the underlying mechanisms remain elusive. In mouse models, JARID1D was an important mediator of both visceral and bone metastases.

View Article and Find Full Text PDF

Background: Differences in the effectiveness of second-generation androgen receptor axis-targeted agents (ARATs) in high-risk metastatic hormone-sensitive prostate cancer (mHSPC) remain unclear. This study aimed to identify the factors influencing the efficacy of ARATs in patients with high-risk mHSPC and compare their long-term effectiveness.

Methods: Four hundred and sixty-six patients with mHSPC treated with ARATs were retrospectively recruited from our hospital and affiliated hospitals of the Kindai Oncology Study Group and Kyoto Prefectural University of Medicine Oncology Study Group between December 2013 and March 2024.

View Article and Find Full Text PDF

Background: In male patients, benign prostate hyperplasia (BPH) and overactive bladder (OAB) secondary to BPH are the primary causes of Lower Urinary Tract Symptoms (LUTS). Recent clinical studies have reported an increased risk of LUTS, particularly severe LUTS conditions, in male asthmatic patients. However, the potential link and mechanism remain unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!